You are here
- Urgent advice regarding management of patients taking lumiracoxib (Prexige)
advice for health professionals, 13 August 2007
- Medicines regulator cancels registration of anti inflammatory drug, Lumiracoxib
media statement, 10 August 2007
|Date agreed:||10 August 2007|
100mg tablets (AUST R 128635)
|Sponsor:||Novartis Pharmaceuticals Pty Ltd|
|Contact:||1800 671 203|
|Reason:||The Therapeutic Goods Administration has cancelled the registration of Lumiracoxib because of serious liver side effects associated with the use of the drug.|
Patients taking Lumiracoxib should stop taking the medicine now and discuss alternative treatments with their doctor.
Recall letters are expected to be dispatched by the sponsor within the next week. Advertisements are also expected to be placed by the sponsor to advise on their returns policy.
Class I defects are potentially life-threatening or could cause a serious risk to health.
Class II defects could cause illness or mistreatment, but are not Class I.
Class III defects may not pose a significant hazard to health, but withdrawal may be initiated for other reasons.
Class I & II recalls are considered to be safety related recalls.